This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Johan Wiström, MD, PhD
University Hospital of Umeå Umeå, Sweden

JAMA. 1995;273(23):1835-1836.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—We previously reported¹ the results of a randomized trial evaluating the immunogenicity of a DNA-recombinant hepatitis B (HB) vaccine (Recombivax-HB, Merck Sharp & Dohme, West Point, Pa) administered intradermally (ID) at a dose of 2 µg or intramuscularly (IM) at a dose of 10 µg to 80 healthy adults at 0,1, and 6 months. Twelve months after the first vaccination, the number of responders (vaccinees with anti-hepatitis B surface antigen [anti-HBsAg] levels 10 IU/L) was found to be significantly higher (P<.0001, ²) in the IM group (36/37, 97%) than in the ID group (21/38, 55%).

Six years (mean, 72 months; range, 66 to 78 months) after initiation of vaccination, we obtained serum from 53 (33 women and 20 men; mean age, 36 years; range, 26 to 61 years) of those 68 vaccinees who initially had anti-HBsAg levels greater than 1 IU/L. Twenty subjects . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?